AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data.

We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization.

AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential.

AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London.

AQEMIA is based in Paris (HQ) and London.